Renee N. Donahue, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 8B01
- Bethesda, MD 20892
Dr. Donahue is a Staff Scientist and Head of the Cellular Immunology Group of the Center for Immuno-Oncology, NCI. She received her Ph.D. in Cell and Molecular Biology from the Pennsylvania State University College of Medicine, and joined the NCI as a Postdoctoral Fellow in 2011. The Cellular Immunology Group interrogates the human immunome of patients prior to immunotherapy and at various times in the immunotherapeutic regimen. Analyses include soluble factors, immune cell subset phenotype and functional assays, and responses to tumor-specific and tumor-associated antigens to help define mechanisms of action and correlates with patient clinical responses.
Areas of Expertise
1) cellular and molecular immunology 2) tumor immunology 3) cancer immunotherapy 4) immune biomarkers
The Center for Immuno-Oncology Translational Research area develops novel immunotherapeutics that are translated from hypothesis-driven preclinical studies to clinical trials. The Cellular Immunology Group is working to characterize the immune response of patients enrolled in our clinical trials to identify patients, prior to or early following therapy, who go on to respond well to various cancer immunotherapies. Our research program develops innovative methods to assess the immune response of cancer patients treated with combination immunotherapies as well as so-called “non-immune”‒based therapies. We investigate soluble analytes and specific immune cell subsets in the peripheral blood of patients to identify potential correlations with clinical responses. We also conduct preclinical and translational research in the areas of tumor immunology and immunotherapy, concentrating on mechanisms of tumor cell‒immune cell interactions and immune cell function, with a focus on combining cancer immunotherapies with novel targeted agents. These studies provide critical information toward the development of more effective immunotherapeutic approaches to cancer.
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (avelumab) treatment in advanced thymoma
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
Renee N. Donahue, Ph.D.
Dr. Renee Donahue received her B.S. in Molecular Biology from Grove City College in 2004, and Ph.D. in Cell and Molecular Biology from the Pennsylvania State University College of Medicine in 2011. She subsequently joined the NIH as a Postdoctoral Fellow in the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, and was appointed as a Staff Scientist in 2017. She is currently head of the Cellular Immunology Group of the Center for Immuno-Oncology's Translational Research area. Dr. Donahue’s current research focuses on investigating the immune response of patients enrolled in our clinical trials, prior to, as well as following therapy, to identify immune signatures that correlate with clinical outcome.